11 September 2013
Two leading pharmacology societies, the British Pharmacological Society (BPS) and the American Society for Pharmacology and Experimental Therapeutics (ASPET), have announced their support for the publication of negative findings from early clinical trials. Their jointly published journal, Pharmacology Research & Perspectives, is at the same time launching an efficient and timely means for researchers to publish negative findings in two important areas: preclinical papers that show a hypothesis to be incorrect, and papers on drugs that have failed in early clinical development that can inform whether further drug development in warranted.
21 June 2013
The British Pharmacological Society (BPS) proudly announces the new Impact Factor results for its journals:
02 May 2013
BPS President-elect, Humphrey Rang contributed to the following Research Fortnight article on the role of publishers in clinical trials transparency.
Publishers of clinical trial results are examining the way they work to try to tackle publication bias and poor access to data.
Following criticisms made by the Wellcome Trust to the House of Commons Science and Technology Committee’s clinical trials inquiry last week, BioMed Central has told Research Fortnight that it is working to improve the International Standard Randomised Controlled Trial Number Register that it administers.
19 April 2013
Boston, MA — April 20, 2013—The American Society for Pharmacology and Experimental Therapeutics (ASPET), British Pharmacological Society (BPS) and John Wiley & Sons have issued a call for papers for their new open access, peer-reviewed journal, Pharmacology Research & Perspectives. The announcement was made as the three partners prepare for the official launch of the journal at the Joint ASPET-BPS Annual Meeting, taking place beginning April 20 as part of the Experimental Biology 2013 conference.